Postmenopausal women taking tirzepatide alongside hormone therapy lost approximately 35% more weight than those using the medication alone, according to a new Mayo Clinic study published in The Lancet Obstetrics, Gynaecology, and Women's Health. The findings suggest that combining menopausal hormone therapy with tirzepatide, a Food and Drug Administration-approved obesity medication, may offer a more effective approach to weight management during a life stage when women face increased cardiometabolic risks .

Menopause brings significant metabolic challenges. As estrogen levels decline, women often experience accelerated weight gain and increased vulnerability to serious health conditions, including cardiovascular disease and type 2 diabetes. The Mayo Clinic research team analyzed data from 120 adults with overweight or obesity who received tirzepatide treatment for at least 12 months, comparing outcomes between those who also used hormone therapy and those who did not .

What Explains the 35% Weight Loss Difference?

The study's findings point to a potential biological synergy between estrogen and GLP-1 (glucagon-like peptide-1) medications. GLP-1 agonists like tirzepatide work by mimicking a natural hormone that regulates appetite and blood sugar. Preclinical research suggests that estrogen may enhance the appetite-suppressing effects of these drugs, creating a more powerful combined effect .

However, researchers emphasize important caveats. Because this was an observational study rather than a randomized controlled trial, the team cannot definitively say that hormone therapy caused the additional weight loss. Alternative explanations exist: women using hormone therapy may have already been engaged in healthier lifestyle behaviors, or relief from menopausal symptoms like hot flashes and night sweats may have improved sleep quality and overall well-being, making it easier to stick with dietary and physical activity changes .

"In this observational study, women who used menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone. Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss," explained Maria Daniela Hurtado Andrade, M.D., Ph.D., endocrinologist at Mayo Clinic and senior author of the study.

Maria Daniela Hurtado Andrade, M.D., Ph.D., Endocrinologist at Mayo Clinic

Why Does Hormone Therapy Matter for Postmenopausal Women?

Hormone therapy remains the most effective first-line treatment for common menopausal symptoms. Up to 75% of postmenopausal women experience hot flashes and night sweats, conditions that significantly impact quality of life and sleep. Until now, the potential role of hormone therapy in enhancing weight-loss medications had not been thoroughly studied, particularly with newer drugs like tirzepatide .

The Mayo Clinic team filled an important research gap. Earlier studies had suggested that women using hormone therapy might lose more weight with GLP-1-based drugs like semaglutide, but comparable data on tirzepatide had been lacking. This new analysis provides the first evidence that the combination may offer meaningful benefits for postmenopausal women navigating both weight management and hormonal changes .

How to Discuss This Combination Approach With Your Doctor

• Assess Your Menopausal Symptoms: If you experience hot flashes, night sweats, or other bothersome menopausal symptoms, discuss whether hormone therapy might be appropriate for you, independent of weight loss goals.
• Review Your Cardiometabolic Risk: Talk with your healthcare provider about your personal risk for cardiovascular disease, type 2 diabetes, and other weight-related conditions to determine if tirzepatide or similar medications are suitable.
• Ask About Combination Potential: If both hormone therapy and tirzepatide are medically appropriate for you, inquire whether using them together might enhance weight loss outcomes based on emerging research.
• Plan for Lifestyle Support: Discuss how improved sleep and symptom relief from hormone therapy might support your ability to maintain dietary and physical activity changes alongside medication.

The magnitude of the 35% difference in weight loss warrants further investigation. Researchers plan to test these observations in a randomized clinical trial, which would provide stronger evidence about whether hormone therapy truly enhances tirzepatide's effects or whether other factors explain the difference .

"The magnitude of this difference warrants future studies that could help clarify how GLP-1-based obesity medications and menopausal hormone therapy may interact. Interestingly, preclinical data suggest a potential synergy, with estrogen appearing to enhance the appetite-suppressing effects of GLP-1," noted Regina Castaneda, M.D., postdoctoral research fellow at Mayo Clinic and first author of the study.

Regina Castaneda, M.D., Postdoctoral Research Fellow at Mayo Clinic

Future research will also explore whether benefits extend beyond weight loss itself. The next phase of investigation will examine whether hormone therapy enhances tirzepatide's effects on cardiometabolic measures, such as blood pressure, cholesterol levels, and blood sugar control. If confirmed, these findings could reshape how doctors approach obesity treatment in postmenopausal women, offering evidence-based strategies to reduce serious health risks for millions of women in this life stage .